In a report released today, Difei Yang from Mizuho Securities assigned a Buy rating to Aerie Pharma (NASDAQ: AERI), with a price target of $77. The company’s shares closed yesterday at $51.30.
Yang noted:
“We had the opportunity to host lunch for Rubino yesterday. The company began to see strong uptake of Rhopressa following the product launch on and feedback from the salesforce has been very positive. We are confident in management’s ability to execute.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 21.2% and a 53.2% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.
Aerie Pharma has an analyst consensus of Strong Buy, with a price target consensus of $81.75.
See today’s analyst top recommended stocks >>
Based on Aerie Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $40.7 million. In comparison, last year the company had a GAAP net loss of $25.79 million.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AERI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and diseases of the eye. Its products include Rhopressa and Roclatan.
